Khiron Expands Product Offering at UK and Increases Patient Accessibility – Technical420 – Technical420
Khiron Life Sciences Corp. (“Khiron” or the”Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis pioneer with core operations in Latin America and Europe, is pleased to offer an operational update with regards to its source of EU-GMP medical cannabis products to the UK. To help alleviate bottlenecks and stock appointments, the business has established an offshore stock of dried flower, for the express purpose of serving UK patients.
Furthermore, the business is broadening its product portfolio by introducing Khiron 1/14, a high-CBD flower to the UK at Q2/21. This follows a successful launch in Germany, in which it is prescribed for signs like stress, substance use disorder, and migraines. Khiron 1/14 will complement Khiron 20/1, also a high-THC flower, which is already being prescribed to patients in the UK. Prescribing experts will also be able to prescribe smaller amounts of the flower products in 5- g jars (pictured below), thanks to improved capabilities at the provider’s EU-GMP certified satisfaction associate.
Tejinder Virk, President of Khiron Europe, remarked,”The European economy is rising and Khiron is nicely placed through our differentiated education platform, mounting clinical evidence, and EU-GMP accredited products ready for pharmaceutical companies. Our group continues to work diligently to increase patient access to medical cannabis products, and patients will now benefit through greater product range and quantities. In the coming months, we intend to present further cannabis-based health care products from our enrolled Colombian strains, elevating the level of clinical data available to health professionals in the UK.”
Around Khiron Life Sciences Corp..
Khiron is a vertically integrated health and CPG cannabis firm with core operations in Latin America, and operational action in Europe and North America. Khiron is your major medical cannabis supplier in Colombia and the very first firm accredited in Colombia for its cultivation, production, national supply and sales, and global export of the low and higher THC medical cannabis products. The business has stuffed health cannabis prescriptions in Colombia, Peru, Germany and also the United Kingdom, and is positioned to start sales in Mexico and Brazil at 2021.
Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product creation, and agricultural infrastructure to successfully drive prescriptions and brand loyalty. Its Wellbeing unit launched the very first branded CBD skincare brand in Colombia, together with KuidaTM currently marketed in several jurisdictions in Latin America, the US and United Kingdom. The Company is headed by Co-founder and Chief Executive Officer, Alvaro Torres, together with a seasoned and diverse executive team and Board of Managers.
Stop by Khiron on line at investors.khiron.ca and on Instagram @khironlife.
This press release may contain certain”forward-looking information” along with”forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that isn’t historical in nature can constitute back-end info. Khiron undertakes no responsibility to comment on investigations, statements or expectations made by third-parties in respect of Khiron, its own securities, or financial or operating results (as important ). Though Khiron considers that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement was based on expectations, factors and assumptions regarding future events which may prove to be erroneous and therefore are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release will be expressly qualified by this cautionary statement and is created as of the date hereof.
Neither the TSXV nor its own Regulation Services Provider (as the term is defined in the policies of their TSXV) accepts responsibility for the adequacy or accuracy of this press release.
T: +1 -LRB-647-RRB- 556-5750
Europe Communications Manager